Article
Addressing dyslipidemic risk beyond LDL-cholesterol.
The Journal of clinical investigation - 4 Jan 2022
Tall Alan R, Thomas David G, Gonzalez-Cabodevilla Ainara G, Goldberg Ira J
Abstract excerpt
Despite the success of LDL-lowering drugs in reducing cardiovascular disease (CVD), there remains a large burden of residual disease due in part to persistent dyslipidemia characterized by elevated levels of triglyceride-rich lipoproteins (TRLs) and reduced levels of HDL. This form of dyslipidemia is increasing globally as a result of the rising prevalence of obesity and metabolic syndrome. Accumulating evidence...
Topics
- Angiopoietin-Like Protein 3
- Animals
- Apolipoprotein C-III
- Atherosclerosis
- Cholesterol, LDL
- Dyslipidemias
- Foam Cells
- Genetic Variation
- Humans
- Lipoproteins, HDL
- Metabolic Syndrome